Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.

Journal of gynecologic oncology - 1 Nov 2024

Lee Young Joo, Kim Woojin, Hong Soomin, Lee Yong Jae, Lee Jung-Yun, Kim Sang Wun, Kim Sunghoon, Kim Young Tae, Nam Eun Ji

Abstract excerpt

OBJECTIVE: To investigate the efficacy of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in predicting survival outcomes based on breast cancer gene (BRCA) mutational status in epithelial ovarian cancer. METHODS: Medical records of 448 patients diagnosed with epithelial ovarian cancer at a single tertiary institution in Korea were retrospectively analyzed. Area under the curve, sensitivity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CA-125 Antigen

Share to Carcinoma, Ovarian Epithelial

Share to Genes, BRCA1

Share to Membrane Proteins

Share to Ovarian Neoplasms

Share to Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 38670560
DOI: 10.3802/jgo.2024.35.e80
PMCID: PMC11543245

Genes

IDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.PMID 38670560Read ↗

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.Semantic proximity Read ↗

Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian CancerSemantic proximity Read ↗

Human epididymis protein 4 and Lewis y enhance chemotherapeutic resistance in epithelial ovarian cancer through the p38MAPK pathwaySemantic proximity Read ↗

Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detectionSemantic proximity Read ↗

Initial serum CA-125 and HE4 levels as predictors for optimal surgical cytoreduction in patients with stage III epithelial ovarian cancerSemantic proximity Read ↗

Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancerSemantic proximity Read ↗

Clinical utility of human epididymis protein 4Semantic proximity Read ↗

Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinomaSemantic proximity Read ↗

Preoperative predictive factor analysis of ovarian malignant involvement in premenopausal patients with clinical stage I endometrioid endometrial carcinomaSemantic proximity Read ↗

Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motilitySemantic proximity Read ↗

HE4 (WFDC2) gene overexpression promotes ovarian tumor growthSemantic proximity Read ↗

HE4: a new potential early biomarker for the recurrence of ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.